RUTI IMMUNE aims to become the first company in the world to register a broad-spectrum antiviral vaccine based on trained immunity, to be used as a first resource prophylactic agent against new or uncontrollable viral infections such as SARS CoV-2, the causal agent of Covid-19. The lead product, RUTI®, is in advanced clinical stage development as a therapeutic vaccine for drug-resistant tuberculosis and bladder cancer. RUTI IMMUNE has acquired exclusive rights to develop and commercialize RUTI® for prevention and treatment of viral infections. In the current Covid-19 emergency situation, RUTI® advanced stage of development allows for a fast development path, starting with pilot phase II trials to show efficacy and safety in the target populations in preparation to pivotal phase III trials leading to registration and subsequent world-wide deployment of the vaccine.The rational to use a tuberculosis vaccine to prevent respiratory virus morbidities stems for long term observations on Bacille Calmette-Guérin (BCG, the only existing tuberculosis vaccine) pediatric vaccination campaigns resulting in cross protection for pneumonia of unknown origin, Respiratory Syncytial Virus infections, or Yellow Fever Virus infections in vaccinated children or controlled clinical experiments. Over the last 5 years research has shown that this cross protection can be explained by tuberculosis antigens inducing trained immunity, a non-specific, long term stimulation of the innate immune response targeting monocytes and neutrophils. These cell types are first-line, broad-spectrum defensive immune cells that can eliminate viruses from the tissues where they are mobilized or resident. It has been shown that BCG, RUTI® and certain compounds of the cell wall of Mycobacterium induce long term (epigenetic) changes in monocytes and neutrophils that allow for a sharper and more controlled non-antibody mediated response in front of respiratory viruses.